Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB2 | P49721 | 15/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 14/20 | 0.35 |
| ▸ | PSMB10 | P40306 | 6/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 5/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14270308 | 0.84 | CA2 (0.46) | CA2CA9 | |
| SCHEMBL16092972 | 0.84 | CA2 (0.46) | CA2CA9 | |
| SCHEMBL30151424 | 0.83 | EPHX1 (0.40) | PSMB2PSMB5PSMB10PSMB8PSMB1 | |
| SCHEMBL16788844 | 0.83 | ALDH1A1 (0.45) | — | |
| SCHEMBL16092976 | 0.83 | ALDH1A1 (0.45) | — | |
| SCHEMBL30151353 | 0.72 | NOS3 (0.39) | PSMB2PSMB5PSMB10PSMB8PSMB1 | |
| SCHEMBL16092975 | 0.70 | CYP2C19 (0.44) | CA2 | |
| SCHEMBL16788843 | 0.70 | CYP2C19 (0.44) | CA2 | |
| SCHEMBL14270257 | 0.69 | LMNA (0.45) | — | |
| SCHEMBL16092968 | 0.67 | GAA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | PSMB2 4741/4885PSMB5 4611/4885PSMB10 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.